

Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care and Macmillan Cancer Support

Dr Carole Longson
Director, Centre for Health Technology Evaluation
National Institute for Health and Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA

Dear Dr Longson,

Single Technology Appraisal: Lapatinib for women with previously treated advanced or metastatic breast cancer

Thank you for the invitation to comment on the post-appeal appraisal consultation document regarding the use of lapatinib for women who have been previously treated for advanced or metastatic breast cancer. Having reviewed the consultation document and evaluation report, Breakthrough Breast Cancer, Breast Cancer Campaign, Breast Cancer Care and Macmillan Cancer Support have jointly concluded that we have no additional evidence to submit to the Appraisal Committee in relation to our previous responses.

We are disappointed that lapatinib has not been approved for the treatment of women with advanced or metastatic breast cancer whose tumours over-express HER2. As patient organisations, we would like to take this opportunity to once again emphasise how important it is to offer patients greater treatment choice, especially for patients with metastatic disease who often have limited treatment options.

If you require further information please contact

[Redacted contact information]

Yours sincerely,

[Redacted signature]

[Redacted contact information]